Veracyte, Inc.
- Jurisdiction
United States - LEI
529900ESWZRHXOW27Z37 - ISIN
US92337F1075 (VCYT )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€24.04 23.9% overvalued - Financial strength (Piotroski F-Value)
-
7
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
6
/ 7
Profile
Veracyte, Inc. operates as a diagnostics company worldwide. Read full profile
Fundamentals
- Net revenue
€408.67M - Gross margin
67.3% - EBIT
€11.79M - EBIT margin
2.9% - Net income
€22.46M - Net margin
5.5%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Stapley Marc | Chief Executive Officer |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Gilbert Cisneros | July 10, 2025 | $1.00K–$15.00K |
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Cathie Wood |
|
|
|
Sell |
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: May 7, 2024 (Q1 2024)